From: First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Grade
The modification from next cycle
Skin toxicitiesa
≧3
Hold dose of treatment and One level dose down
Hypomagnesaemia
Pulmonary fibrosis
≧2
Withdrawal from study
Infusion reaction
Hold dose of treatment